Alza Corporation

Other

Alza Coporation

Fernando E Gumucio

George V Guittard

David J Kidney

Francisco Jao

Susan M Marks

Patrick S Wong

Jerry D Childers

A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.

Method for the management of incontinence

A composition comprising oxybutynin, a dosage form comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.

Oxybutynin therapy

A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy.

Therapy for neurological diseases

A composition comprising oxybutynin, a device comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.

Dosage form and method for treating incontinence

Dosage form comprising oxybutynin

Tacrine therapy

A composition comprising oxybutynin and a device comprising oxybutynin are disclosed for oxybutynin therapy.

Growing community of inventors

San Jose, CA, United States of America

Fernando E Gumucio